目的 觀察阿法骨化醇軟膠囊聯(lián)合雷洛昔芬治療絕經(jīng)后骨質(zhì)疏松癥的臨床療效。方法 選取2015年1月—2016年1月南陽市骨科醫(yī)院收治的絕經(jīng)后婦女骨質(zhì)疏松癥患者102例，隨機(jī)分為對照組和治療組，每組各51例。對照組患者口服鹽酸雷洛昔芬片，1片/次，1次/d。治療組在對照組的基礎(chǔ)上口服阿法骨化醇軟膠囊，1粒/次，1次/d。兩組患者均治療6個月。評價(jià)治療后兩組患者臨床療效，同時(shí)比較治療前后兩組骨強(qiáng)度、骨代謝標(biāo)記物含量和不良反應(yīng)差異。結(jié)果 治療后，對照組和治療組臨床總有效率分別為82.35%、96.08%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者骨密度和骨礦含量均明顯升高（P< 0.05）；且治療后治療組骨強(qiáng)度指標(biāo)明顯高于對照組（P< 0.05）。治療后，兩組患者I型膠原交聯(lián)氨基端肽（NTX I）、I型膠原交聯(lián)羧基端肽（CTX I）、抗酒石酸酸性磷酸酶5b（TRACP5b）和血骨鈣素（BGP）含量均明顯降低（P< 0.05）；且治療組患者的骨代謝標(biāo)記物含量明顯低于對照組（P< 0.05）。結(jié)論 阿法骨化醇軟膠囊聯(lián)合雷洛昔芬治療絕經(jīng)后骨質(zhì)疏松癥療效較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical efficacy of Alfacalcidol Soft Capsules combined with raloxifene in treatment of postmenopausal osteoporosis. Methods Women (106 cases) with postmenopausal osteoporosis in Nanyang Orthopedic Hospital from January 2015 to January 2016 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Raloxifene Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Alfacalcidol Soft Capsules on the basis of the control group, 1 grain/time, once daily. Patients in two groups were treated for 6 months. After treatment, clinical efficacy was evaluated, and bone intensity, bone metabolic markers, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 82.35% and 96.08%, respectively, and there were differences between two groups (P < 0.05). After treatment, the bone density and bone mineral content in two groups were significantly increased (P < 0.05). And the bone intensity indexes in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the NTX I, CTX I, TRACP5b, and BGP in two groups were significantly decreased (P < 0.05). And the levels of bone metabolic markers in treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Alfacalcidol Soft Capsules combined with raloxifene has good effects in treatment of postmenopausal osteoporosis, which has a certain clinical application value.